Cristal Therapeutics develops the next generation of targeted nanomedicines to treat various diseases, in particular cancer. With CriPec® nanomedicines Cristal Therapeutics aims to maximize drug efficacy whilst minimizing side effects.
Cristal Therapeutics was founded by Cristianne Rijcken, PhD, and Joost Holthuis, PhD. in 2011, as a spin-off of the Department of Pharmaceutal Sciences of the Utrecht University, The Netherlands. The company is based in Maastricht, The Netherlands.